GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Total Current Liabilities

BCAL Diagnostics (ASX:BDX) Total Current Liabilities : A$1.22 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. BCAL Diagnostics's total current liabilities for the quarter that ended in Dec. 2023 was A$1.22

BCAL Diagnostics Total Current Liabilities Historical Data

The historical data trend for BCAL Diagnostics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Total Current Liabilities Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Total Current Liabilities
0.95 2.26

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Liabilities Get a 7-Day Free Trial 0.32 0.95 0.41 2.26 1.22

BCAL Diagnostics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

BCAL Diagnostics's Total Current Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.02+0.165
+Other Current Liabilities+Current Deferred Liabilities
=0.076+0
=2.26

BCAL Diagnostics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.769+0.364
+Other Current Liabilities+Current Deferred Liabilities
=0.083+0
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

BCAL Diagnostics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Total Current Liabilities
Comparable Companies
ASX:GTG ASX:CTE ASX:LDX ASX:IBX ASX:RHY ASX:IIQ ASX:GSS ASX:MAP TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX
Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
Website
https://www.bcaldiagnostics.com
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.

BCAL Diagnostics (ASX:BDX) Headlines

From GuruFocus

Becton Dickinson and Co at Bank of America Healthcare Conference Transcript

By GuruFocus Research • 01-22-2024

BD Board Declares Dividend

By PRNewswire • 01-23-2024

Q4 2022 Becton Dickinson and Co Earnings Call Transcript

By GuruFocus Research • 01-22-2024

Becton Dickinson and Co at JPMorgan Healthcare Conference Transcript

By GuruFocus Research • 01-22-2024

Q3 2023 Becton Dickinson and Co Earnings Call Transcript

By GuruFocus Research • 01-22-2024

Becton Dickinson and Co Annual Shareholders Meeting Transcript

By GuruFocus Research • 01-22-2024

Q2 2023 Becton Dickinson and Co Earnings Call Transcript

By GuruFocus Research • 01-22-2024

Q1 2023 Becton Dickinson and Co Earnings Call Transcript

By GuruFocus Research • 01-22-2024

BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics

By PRNewswire • 01-23-2024

Q1 2022 Becton Dickinson and Co Earnings Call Transcript

By GuruFocus Research • 01-22-2024